# Clinical Significance of Elevated Levels of Soluble‐Form Immune Checkpoint Molecules in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma

**Authors:** Shigeo Fuji, Junya Makiyama, Kuniko Takano, Ilseung Choi, Takeo Suzuki, Chihiro Suminaka, Mao Kuroishi, Yosuke Iwasaki, Hidenori Kasahara, Yuma Tada, Yasuhiro Shingai, Sayako Yuda, Takafumi Yokota, Jun Ishikawa

PMC · DOI: 10.1002/jha2.70046 · 2025-06-26

## TL;DR

This study shows that high levels of soluble immune checkpoint molecules are linked to worse outcomes in aggressive adult T-cell leukemia-lymphoma patients.

## Contribution

The study identifies elevated soluble PD-1, PD-L1, and CTLA-4 as novel adverse prognostic markers in aggressive ATL.

## Key findings

- Soluble PD-1, PD-L1, and CTLA-4 levels were significantly higher in aggressive ATL compared to indolent ATL.
- Elevated soluble IC levels correlated strongly with soluble IL-2R and predicted adverse prognosis.
- These markers may serve as potential indicators of immune status and disease severity in ATL.

## Abstract

Immune checkpoint (IC) pathways, including programmed death protein 1 (PD‐1), its ligand PD‐L1, and CTLA‐4, mediate negative regulatory signals in immune responses. Recent studies in autoimmune diseases and malignancies reported that the presence of the soluble form of these ICs would reflect the overall immune status. We assessed the clinical significance of these soluble‐form ICs in HTLV‐1 carriers and adult T‐cell leukemia‐lymphoma (ATL) patients.

After obtaining informed consent, plasma from HTLV‐1 carriers and ATL patients was prospectively collected in participating centers. Plasma concentrations of soluble‐form PD‐1, PD‐L1, and CTLA‐4 (sPD‐1, sPD‐L1, and sCTLA‐4) were measured.

Ninety‐six cases were included (HTLV‐1 carriers, n = 4; indolent ATL, n = 14; aggressive ATL, n = 78). The median age at sampling was 65.5 (range, 23–85) years. Soluble factors levels were significantly higher in aggressive ATL than in indolent ATL (sPD‐1, p = 0.003; sPD‐L1, p = 0.017; sCTLA‐4, p < 0.001). These markers were strongly correlated with soluble IL‐2R (sPD‐1, r = 0.80; sPD‐L1, r = 0.61; sCTLA‐4, r = 0.82). Elevated soluble IC levels were significant adverse prognostic factors.

Soluble IC levels were significantly higher in aggressive ATL than in indolent ATL, and predicted an adverse prognosis. Their clinical significance should be investigated in larger studies.

## Linked entities

- **Proteins:** PDCD1 (programmed cell death 1), CD274 (CD274 molecule), CTLA4 (cytotoxic T-lymphocyte associated protein 4), IL2RA (interleukin 2 receptor subunit alpha)
- **Diseases:** adult T-cell leukemia-lymphoma (MONDO:0019471)

## Full-text entities

- **Genes:** PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, SPDL1 (spindle apparatus coiled-coil protein 1) [NCBI Gene 54908] {aka CCDC99}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, HOXD13 (homeobox D13) [NCBI Gene 3239] {aka BDE, BDSD, HOX4I, SPD, SPD1}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}
- **Diseases:** malignancies (MESH:D009369), autoimmune diseases (MESH:D001327), ATL (MESH:D015459)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human T-cell leukemia virus type I (no rank) [taxon 11908]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12199990/full.md

---
Source: https://tomesphere.com/paper/PMC12199990